But while digitalisation is critical, the future of healthcare will likely have space for both traditional players and technological innovators. While tech innovators are often portrayed as disrupting traditional aspects of the industry, their relationship can also be complementary rather than just antagonistic, focusing on collaborative problem-solving and reducing duplicating solutions based on each other’s unique strengths.
In healthcare delivery, for instance, 'There will be new ways of delivering care that will not be completely traditional. But it will not be 100% technology-driven and futuristic [either], because certain things will need to be grounded in practices that have been proven and in the comfort level of people who are actually in the field or on the ground,' said Dr. Chern Chet Yong, Asia Ecosystem, 22Health Ventures.
There is a lot that newer tech companies can learn from the years of on-the-ground experience of healthcare organisations and practitioners. These more traditional players, on the other hand, can benefit from working closely with Singapore’s health-tech sector, which has remained resilient despite an overall decline in healthtech deals and valuations around the world in 2022, perhaps on the back of the country’s dynamic tech ecosystem, favourable business environment, and robust infrastructure.
It’s a sector that has “come of age,” according to a 2022 venture capital report by Enterprise Singapore and Deal Street Asia, experiencing a drop in deal value and volume but, at the same time, witnessing sizable investments, such as digital health company Biofurmis’s US$300 million Series D funding in 2022, which propelled the firm to unicorn status.